|
|
Post by mssciguy on Dec 15, 2015 12:24:12 GMT -5
I highly doubt it is low awareness in the Endocronology field. They all have continuing education, they all read journals, they are aware of Afrezza. Patients may not be aware, but you are just spreading lies to believe that the medical community is not aware of Afrezza at this point. I strongly disagree with your comments above traderdennis. In general Endos are simply not that familiar with how afrezza works yet. On going training for docs is very important. Also, your comments above about lung issues is a joke. Yeah, the classification as "preventative" in addition to "prandial" if true for more insurers will be the watershed moment that separates Afrezza from all other current competition ... Many other very positive developments, like the SD mtg feedback, patients finally getting scripts for low copay, athletic types on Twitter praising Afrezza for more freedom to work out (bonus health!), the unheard-of low, optimally healthy A1c's All systems are go. |
|
|
|
Post by traderdennis on Dec 15, 2015 13:41:25 GMT -5
I highly doubt it is low awareness in the Endocronology field. They all have continuing education, they all read journals, they are aware of Afrezza. Patients may not be aware, but you are just spreading lies to believe that the medical community is not aware of Afrezza at this point. I strongly disagree with your comments above traderdennis. In general Endos are simply not that familiar with how afrezza works yet. On going training for docs is very important. Also, your comments above about lung issues is a joke. That was the same quote I received when the stock price was above $7 . Keep putting your head in the sand, while the HMO organization is known for their conservative care overall, the endocronology department at this major HMO voted unanimously not to use Afrezza back in January, sighting delivering hormones through the pulmonary system as a concern. There is a reason why after a year their less than 100 doctors prescribing per Afrezza users website. These docs go to meetings, attend the ADA conventions, keep up on current treatments. Time to dig your head out of the sand saxcmann. |
|
|
|
Post by mssciguy on Dec 15, 2015 13:47:23 GMT -5
I strongly disagree with your comments above traderdennis. In general Endos are simply not that familiar with how afrezza works yet. On going training for docs is very important. Also, your comments above about lung issues is a joke. That was the same quote I received when the stock price was above $7 . Keep putting your head in the sand, while the HMO organization is known for their conservative care overall, the endocronology department at this major HMO voted unanimously not to use Afrezza back in January, sighting delivering hormones through the pulmonary system as a concern. There is a reason why after a year their less than 100 doctors prescribing per Afrezza users website. These docs go to meetings, attend the ADA conventions, keep up on current treatments. Time to dig your head out of the sand saxcmann. So far, it's been this: Newton's First Law Newton's first law of motion - sometimes referred to as the law of inertia. An object at rest stays at rest and an object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force. Next it will be this Newton's second law of motion pertains to the behavior of objects for which all existing forces are not balanced. The second law states that the acceleration of an object is dependent upon two variables - the net force acting upon the object and the mass of the object. The acceleration of an object depends directly upon the net force acting upon the object. Did I get that right @kastanes ? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 15, 2015 13:53:58 GMT -5
That was the same quote I received when the stock price was above $7 . Keep putting your head in the sand, while the HMO organization is known for their conservative care overall, the endocronology department at this major HMO voted unanimously not to use Afrezza back in January, sighting delivering hormones through the pulmonary system as a concern. There is a reason why after a year their less than 100 doctors prescribing per Afrezza users website. These docs go to meetings, attend the ADA conventions, keep up on current treatments. Time to dig your head out of the sand saxcmann. So far, it's been this: Newton's First Law Newton's first law of motion - sometimes referred to as the law of inertia. An object at rest stays at rest and an object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force. Next it will be this Newton's second law of motion pertains to the behavior of objects for which all existing forces are not balanced. The second law states that the acceleration of an object is dependent upon two variables - the net force acting upon the object and the mass of the object. The acceleration of an object depends directly upon the net force acting upon the object. Did I get that right @kastanes ? If F= MA, then can we consider Caremark to be part of the M? You decide: www.pbmi.com/2015/04/2014-pbm-market-share/ |
|
|
|
Post by mssciguy on Dec 15, 2015 14:19:11 GMT -5
So far, it's been this: Newton's First Law Newton's first law of motion - sometimes referred to as the law of inertia. An object at rest stays at rest and an object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force. Next it will be this Newton's second law of motion pertains to the behavior of objects for which all existing forces are not balanced. The second law states that the acceleration of an object is dependent upon two variables - the net force acting upon the object and the mass of the object. The acceleration of an object depends directly upon the net force acting upon the object. Did I get that right @kastanes ? If F= MA, then can we consider Caremark to be part of the M? You decide: www.pbmi.com/2015/04/2014-pbm-market-share/And the force is the (so far almost non-existent) sales force from Sanofi. The slow launch is beginning to make sense now? |
|
|
|
Post by dreamboatcruise on Dec 15, 2015 14:25:50 GMT -5
@scotta + mssciguy... lol, think you've hit on the equation. Though with respect to payers you might need to consider the concept of friction... or perhaps based on formularylookup.com it might be stiction. |
|
|
|
Post by biffn on Dec 15, 2015 15:00:57 GMT -5
Traderdennis:
Coumpound -
I wrote back in Q1 that my Endocronologist was not writing Afrezza RX's because of "His" concern of administering a hormone through the pulmonary system. Also it was a unanimous decision by all endo's in the HMO. I would not be surprised if this is a shared opinion by many doc's. I was labeled a Fudster by that comment. Unfortunately I was not wrong but my Jan 2016 long calls are going to expire worthless. At least I will of lost less money with them than I would of holding the actual stock.
What about the long history of pulmonary treatment of asthma using corticosteroids (i.e., HORMONES)? " "His" concern of administering a hormone through the pulmonary system" is a straw man argument.
|
|
|
|
Post by traderdennis on Dec 15, 2015 18:07:24 GMT -5
Traderdennis:
Coumpound -
I wrote back in Q1 that my Endocronologist was not writing Afrezza RX's because of "His" concern of administering a hormone through the pulmonary system. Also it was a unanimous decision by all endo's in the HMO. I would not be surprised if this is a shared opinion by many doc's. I was labeled a Fudster by that comment. Unfortunately I was not wrong but my Jan 2016 long calls are going to expire worthless. At least I will of lost less money with them than I would of holding the actual stock.
What about the long history of pulmonary treatment of asthma using corticosteroids (i.e., HORMONES)? " "His" concern of administering a hormone through the pulmonary system" is a straw man argument. I am not in the medical field. I do not believe that is an equal statement since asthma is a condition that effects the lungs directory and treatment is for the lungs and pulmanary system. |
|
|
|
Post by beardawg on Dec 15, 2015 18:22:46 GMT -5
Traderdennis:
Coumpound -
I wrote back in Q1 that my Endocronologist was not writing Afrezza RX's because of "His" concern of administering a hormone through the pulmonary system. Also it was a unanimous decision by all endo's in the HMO. I would not be surprised if this is a shared opinion by many doc's. I was labeled a Fudster by that comment. Unfortunately I was not wrong but my Jan 2016 long calls are going to expire worthless. At least I will of lost less money with them than I would of holding the actual stock.
What about the long history of pulmonary treatment of asthma using corticosteroids (i.e., HORMONES)? " "His" concern of administering a hormone through the pulmonary system" is a straw man argument. I am not in the medical field. I do not believe that is an equal statement since asthma is a condition that effects the lungs directory and treatment is for the lungs and pulmanary system. If they are afraid because they think it presents a cancer risk, it doesn't matter if the treatment is meant for the lungs or not. If hormones cause it, it will cause it regardless of the treatment area. As a matter of fact, I'd be more worried about treatments that are meant to stay in the lungs (asthma corticosteroid) over one that simply passes through (technosphere insulin). |
|
|
|
Post by BlueCat on Dec 16, 2015 1:10:08 GMT -5
And the force is the (so far almost non-existent) sales force from Sanofi. The slow launch is beginning to make sense now?
The Force is arriving in 3 days .........
Ah ok. I'll have my Forrest Gump moment and go home now.
|
|
